Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2015.00135
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Comparison of Responses of Human Melanoma Cell Lines to MEK and BRAF Inhibitors

Frontiers in Genetics
GeneticsMolecular Medicine
2013English

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery
Oncology
2017English

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

Cancers
Cancer ResearchOncology
2019English

PI3K Inhibitors Synergize With FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Mutant Endometrial Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2017English

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma

iScience
Multidisciplinary
2019English

BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

Real‐World Toxicity Experience With BRAF/MEK Inhibitors in Patients With Erdheim‐Chester Disease

Oncologist
Cancer ResearchMedicineOncology
2019English

BRAF Mutant Colorectal Cancer: ErbB2 Expression Levels as Predictive Factor for the Response to Combined BRAF/ErbB Inhibitors

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy